• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    6/14/23 1:12:22 PM ET
    $AAMC
    $AFRM
    $AGL
    $AHI
    Real Estate
    Finance
    Finance: Consumer Services
    Finance
    Get the next $AAMC alert in real time by email

    Gainers

    • WeTrade Group, Inc. (NASDAQ:WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial intelligence.
    • Cyxtera Technologies, Inc. (NASDAQ:CYXT) shares climbed 71.5% to $0.0717 after dropping 12% on Tuesday.
    • Blue Water Biotech, Inc. (NASDAQ:BWV) gained 67% to $1.32 after the company acquired six FDA-approved drugs across various treatment areas
    • WiSA Technologies, Inc. (NASDAQ:WISA) shares surged 51.7% to $1.9575. WiSA Technologies started taking pre-orders for WiSA E multichannel audio development kits.
    • NextDecade Corporation (NASDAQ:NEXT) gained 35% to $6.93 after the company announced it has entered into framework agreements with Global Infrastructure Partners and TotalEnergies to support the development of the Rio Grande LNG project.
    • Ideanomics, Inc. (NASDAQ:IDEX) rose 27.6% to $0.1177.
    • Inventiva S.A. (NASDAQ:IVA) shares climbed 22.3% to $4.49 after the company announced its Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD achieved its primary efficacy endpoint.
    • Greenidge Generation Holdings Inc. (NASDAQ:GREE) gained 21.3% to $1.93.
    • Coherent Corp. (NYSE:COHR) surged 17% to $50.13.
    • Leju Holdings Limited (NYSE:LEJU) rose 16.9% to $2.9699.
    • IPG Photonics Corporation (NASDAQ:IPGP) climbed 16.1% to $135.92. Raymond James upgraded IPG Photonics from Market Perform to Outperform and announced a $170 price target.
    • Akoya Biosciences, Inc. (NASDAQ:AKYA) gained 15.5% to $7.57.
    • Gossamer Bio, Inc. (NASDAQ:GOSS) surged 13.6% to $1.3410.
    • Microvast Holdings, Inc. (NASDAQ:MVST) jumped 12.7% to $1.7698.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) shares gained 11.7% to $0.0696. T2 Biosystems recently reported a clinical collaboration with Vanderbilt University Medical Center to implement and evaluate the T2Bacteria panel for clinical use.
    • Nikola Corporation (NASDAQ:NKLA) rose 9.4% to $1.00 after jumping over 19% on Tuesday.
    • Matterport, Inc. (NASDAQ:MTTR) gained 8.8% to $3.1898. Matterport announced Genesis, a generative AI initiative to transform how buildings are designed, built, and managed.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) climbed 8.7% to $0.8586. Accelerate Diagnostics recently posted downbeat quarterly results.
    • NightHawk Biosciences, Inc. (NYSE:NHWK) shares gained 7.8% to $0.67.

    Losers

    • Tenon Medical, Inc. (NASDAQ:TNON) shares dipped 56.5% to $0.2693 after it priced its public offering of $5.6M at $0.56 per unit.
    • Advanced Health Intelligence Ltd. (NASDAQ:AHI) fell 39.3% to $0.9102 after dropping over 37% on Tuesday. Advanced Health Intelligence said it will undertake AUD$5 million private placement.
    • Cineverse Corp. (NASDAQ:CNVS) shares fell 37.1% to $2.24 after the company reported pricing of $8 million public offering.
    • IperionX Limited (NASDAQ:IPX) dropped 29.2% to $9.35. IperionX shares climbed over 100% on Tuesday after the company announced it will produce titanium components for the Ford Motor Company.
    • IO Biotech, Inc. (NASDAQ:IOBT) fell 23.8% to $1.63 after the company increased the enrolled patients in Phase 3 trial to 380, potentially accelerating the time to reach the primary end point of progression free survival.
    • FLJ Group Limited (NASDAQ:FLJ) dropped 22.7% to $0.3095.
    • MicroVision, Inc. (NASDAQ:MVIS) fell 22.4% to $4.9401 after the company filed for a mixed shelf offering.
    • Eastside Distilling, Inc. (NASDAQ:EAST) fell 22.1% to $4.8505 after the company disclosed business and financial updates.
    • MIND Technology, Inc. (NASDAQ:MIND) declined 20.6% to $0.6208 following wider-than-expected quarterly loss.
    • Singularity Future Technology Ltd. (NASDAQ:SGLY) fell 18.1% to $0.42.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) dropped 16.6% to $0.6407. SMX achieved 100% year-to-date growth in commercialization driven by client adoption & transformation across industries.
    • agilon health, inc. (NYSE:AGL) dropped 14.2% to $18.08.
    • Allogene Therapeutics, Inc. (NASDAQ:ALLO) dropped 13.3% to $4.94. Allogene Therapeutics reported the departure of CFO Eric T. Schmidt.
    • Mullen Automotive, Inc. (NASDAQ:MULN) dipped 13.2% to $0.279.
    • Humana Inc. (NYSE:HUM) fell 13.1% to $445.64. Shares of several health insurers traded lower following comments from UnitedHealth Group CEO highlighting an increase in elevated volumes of non-urgent surgeries, which has increased fears of higher costs for insurers.
    • agilon health, inc. (NYSE:AGL) dropped 12.2% to $18.45. Evercore ISI Group initiated coverage on Agilon Health with an In-Line rating and announced a price target of $22.5.
    • Bruush Oral Care Inc. (NASDAQ:BRSH) fell 12% to $0.3346 after jumping over 22% on Tuesday.
    • Altisource Asset Management Corporation (NASDAQ:AAMC) declined 11.8% to $54.35. Altisource Asset Management reported favorable ruling from New York Appellate Court.
    • Logitech International S.A. (NASDAQ:LOGI) shares dropped 11.8% to $56.35. Logitech said President and CEO Bracken Darrell will be departing to pursue another opportunity.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) fell 11.5% to $5.62.
    • Affirm Holdings, Inc. (NASDAQ:AFRM) fell 9.6% to $16.93 after BTIG initiated coverage on the stock with a Sell rating and announced a $10 price target.
    • Centene Corporation (NYSE:CNC) dropped 7.7% to $64.11. Shares of several health insurers traded lower following comments from UnitedHealth Group CEO highlighting an increase in elevated volumes of non-urgent surgeries, which has increased fears of higher costs for insurers.
    • UnitedHealth Group Incorporated (NYSE:UNH) shares declined 7.1% to $456.70 after the company's CEO highlighted an increase in elevated volumes of non-urgent surgeries, which has increased fears of higher costs for insurers.
    • Icahn Enterprises L.P. (NASDAQ:IEP) fell 7% to $28.40.
    • Cinemark Holdings, Inc. (NYSE:CNK) dropped 6.6% to $17.18. B. Riley Securities downgraded Cinemark from Buy to Neutral and lowered the price target from $21 to $20.
    • Kura Oncology, Inc. (NASDAQ:KURA) shares fell 5.3% to $12.05 after the company reported commencement of $100 million public offering of common stock and pre-funded warrants.
    • RadNet, Inc. (NASDAQ:RDNT) shares fell 5.2% to $31.21. Radnet priced an underwritten offering of 7.575 million shares at $29.75 per share, with gross proceeds of approximately $225 million.

     

    Now Read This: Kroger Likely To Report Flat Q2 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Get the next $AAMC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAMC
    $AFRM
    $AGL
    $AHI

    CompanyDatePrice TargetRatingAnalyst
    Affirm Holdings Inc.
    $AFRM
    2/20/2026$55.00Neutral
    Robert W. Baird
    Cineverse Corp.
    $CNVS
    2/19/2026$12.00Speculative Buy → Buy
    The Benchmark Company
    IPG Photonics Corporation
    $IPGP
    2/13/2026$180.00Strong Buy → Outperform
    Raymond James
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    NextDecade Corporation
    $NEXT
    2/6/2026$7.00Overweight
    CapitalOne
    Affirm Holdings Inc.
    $AFRM
    2/3/2026$76.00Equal-Weight → Overweight
    Morgan Stanley
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Inventiva S.A.
    $IVA
    1/28/2026$18.00Overweight
    Barclays
    More analyst ratings

    $AAMC
    $AFRM
    $AGL
    $AHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Affirm with a new price target

    Robert W. Baird initiated coverage of Affirm with a rating of Neutral and set a new price target of $55.00

    2/20/26 8:23:24 AM ET
    $AFRM
    Finance: Consumer Services
    Finance

    Cineverse upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Cineverse from Speculative Buy to Buy and set a new price target of $12.00

    2/19/26 7:46:51 AM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    IPG Photonics downgraded by Raymond James with a new price target

    Raymond James downgraded IPG Photonics from Strong Buy to Outperform and set a new price target of $180.00

    2/13/26 8:29:21 AM ET
    $IPGP
    Semiconductors
    Technology

    $AAMC
    $AFRM
    $AGL
    $AHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres Tech/Chief Product Off Huidor Mark Antonio bought $75,000 worth of shares (37,500 units at $2.00), increasing direct ownership by 25% to 190,061 units (SEC Form 4)

    4 - Cineverse Corp. (0001173204) (Issuer)

    2/17/26 9:57:19 PM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    CFO Lindsey Mark Wayne bought $70,000 worth of shares (35,000 units at $2.00), increasing direct ownership by 29% to 154,168 units (SEC Form 4)

    4 - Cineverse Corp. (0001173204) (Issuer)

    2/17/26 9:54:43 PM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    Chief Motion Pictures Officer Macias Yolanda sold $5,297 worth of shares (2,189 units at $2.42) and bought $60,000 worth of shares (30,000 units at $2.00), increasing direct ownership by 30% to 121,760 units (SEC Form 4)

    4 - Cineverse Corp. (0001173204) (Issuer)

    2/17/26 9:54:04 PM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    $AAMC
    $AFRM
    $AGL
    $AHI
    SEC Filings

    View All

    Gossamer Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Gossamer Bio, Inc. (0001728117) (Filer)

    2/23/26 8:30:24 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centene Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - CENTENE CORP (0001071739) (Filer)

    2/20/26 9:32:27 PM ET
    $CNC
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by agilon health inc.

    DEFA14A - agilon health, inc. (0001831097) (Filer)

    2/20/26 4:01:17 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AAMC
    $AFRM
    $AGL
    $AHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Corp Controller and CAO Buttarazzi Mary E. was granted 1,789 shares, increasing direct ownership by 46% to 5,684 units (SEC Form 4)

    4 - IPG PHOTONICS CORP (0001111928) (Issuer)

    2/20/26 4:40:53 PM ET
    $IPGP
    Semiconductors
    Technology

    SVP, Chief Revenue Officer Ness Trevor was granted 4,621 shares, increasing direct ownership by 12% to 41,827 units (SEC Form 4)

    4 - IPG PHOTONICS CORP (0001111928) (Issuer)

    2/20/26 4:40:02 PM ET
    $IPGP
    Semiconductors
    Technology

    SVP, Chief Financial Officer Mammen Timothy Pv was granted 6,146 shares, increasing direct ownership by 7% to 90,723 units (SEC Form 4)

    4 - IPG PHOTONICS CORP (0001111928) (Issuer)

    2/20/26 4:39:11 PM ET
    $IPGP
    Semiconductors
    Technology

    $AAMC
    $AFRM
    $AGL
    $AHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    National CineMedia, Inc. to Release Fourth Quarter and Full Year 2025 Results on February 26, 2026

    National CineMedia, Inc. (NASDAQ:NCMI), the managing member of National CineMedia, LLC ("NCM LLC"), the operator of the largest cinema advertising platform in the U.S., plans to issue its fourth quarter and full year 2025 earnings results after the market closes on Thursday, February 26, 2026. A conference call and audio webcast to discuss the results will take place at 5:00 p.m. Eastern Time. The conference call can be accessed by dialing 1-844-826-3033 or for international participants 1-412-317-5185. Participants should register at least 15 minutes prior to the commencement of the call to register, download, and install necessary audio software. Additionally, a live audio webcast will

    2/19/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    $AAMC
    $AFRM
    $AGL
    $AHI
    Financials

    Live finance-specific insights

    View All

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    National CineMedia, Inc. to Release Fourth Quarter and Full Year 2025 Results on February 26, 2026

    National CineMedia, Inc. (NASDAQ:NCMI), the managing member of National CineMedia, LLC ("NCM LLC"), the operator of the largest cinema advertising platform in the U.S., plans to issue its fourth quarter and full year 2025 earnings results after the market closes on Thursday, February 26, 2026. A conference call and audio webcast to discuss the results will take place at 5:00 p.m. Eastern Time. The conference call can be accessed by dialing 1-844-826-3033 or for international participants 1-412-317-5185. Participants should register at least 15 minutes prior to the commencement of the call to register, download, and install necessary audio software. Additionally, a live audio webcast will

    2/19/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    $AAMC
    $AFRM
    $AGL
    $AHI
    Leadership Updates

    Live Leadership Updates

    View All

    Countdown to Cinema's Biggest Night with Cinemark's Oscars® Movie Week Festival

    Movie lovers can experience the year's most celebrated films on the big screen with festival passes, individual tickets and exclusive perks including specialty merchandise. This year's event is presented by Focus Features' highly anticipated romantic drama "Sense and Sensibility," arriving in theaters on September 11. Cinemark Holdings, Inc., one of the largest and most influential theatrical exhibition companies in the world, invites movie lovers nationwide to immerse themselves in Hollywood's finest storytelling during its annual Oscars® Movie Week festival. From Monday, March 9 through Sunday, March 15, audiences can enjoy participating titles across Best Picture, Live Action Short F

    1/22/26 8:30:00 AM ET
    $CNK
    Movies/Entertainment
    Consumer Discretionary

    Coherent Corp. Announces Timing of FY2026 Second Quarter Earnings Release

    SAXONBURG, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE:COHR) ("Coherent," "We," or the "Company"), a global leader in photonics, announced today that it will release its financial results for the quarter ended December 31, 2025, on Wednesday, February 4, after the New York Stock Exchange closes. The release will be followed by a live audio webcast at 4:30 p.m. ET to discuss the results. The Company invites investors to join the live audio webcast at coherent.com/company/ investor-relations/financial-webcasts. The webcast will be recorded, and a replay will be available within 24 hours after the live audio webcast on the company's website. About Coherent Coherent is the g

    1/21/26 4:05:00 PM ET
    $COHR
    Electronic Components
    Technology

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAMC
    $AFRM
    $AGL
    $AHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kura Oncology Inc.

    SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

    12/5/24 6:55:37 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by Microvast Holdings Inc.

    SC 13D/A - Microvast Holdings, Inc. (0001760689) (Subject)

    11/21/24 9:41:30 PM ET
    $MVST
    Industrial Machinery/Components
    Miscellaneous

    $AAMC
    $AFRM
    $AGL
    $AHI
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care